<DOC>
	<DOCNO>NCT02351232</DOCNO>
	<brief_summary>A randomized placebo-controlled clinical trial investigate effect Liraglutide add-on intensive insulin therapy overweight insulin pump treat type 1 diabetes patient suboptimal glycemic control .</brief_summary>
	<brief_title>The Lira Pump Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes ≥ 1 year BMI &gt; 25 kg/m2 Insulin pump ≥ 1 year HbA1c &gt; 58 mmol/mol Use carbohydrate counting insulin pump bolus calculator Gastroparesis Impaired renal function ( eGFR &lt; 60 ml/min/1.73m2 ) Liver disease ALAT &gt; 2.5 time upper limit reference interval Acute chronic pancreatitis history chronic pancreatitis idiopathic acute pancreatitis Inflammatory bowel disease History cancer ( except basal cell skin cancer ) investigator opinion could interfere result trial , cancer past 5 year Thyroid adenoma Subjects personal family history MTC MEN2 Use antidiabetic medicine ( insulin ) , corticosteroid drug affect glucose metabolism study period within 30 day prior study start Known suspect alcohol drug abuse Other concomitant medical psychological condition accord investigator 's assessment make patient unsuitable study participation Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method . Simultaneous participation clinical intervention trial Known suspect hypersensitivity Liraglutide Inability understand patient information give inform consent Acute treatment require proliferative retinopathy maculopathy ( macular oedema ) Any Cardiac disorder investigator opinion could interfere safety result trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>